Drug Detail

Drug Name Fludarabine
Trade Name Fludara
Synonyms FAMP|Fludarabine phosphate
Drug Descriptions

Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)

DrugClasses

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
lenalidomide + Fludarabine + Melphalan
Busulfan + Fludarabine
Cytarabine + Fludarabine + Idarubicin
Fludarabine phosphate + Inotuzumab ozogamicin + Melphalan + Tacrolimus
Cytarabine + Filgrastim + Fludarabine + Idarubicin +Mitoxantrone
Allopurinol + Cyclophosphamide + Fludarabine
Fludarabine Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)
ALT-803 + Cyclophosphamide + Fludarabine phosphate
Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin + Idarubicin
HPVSTs + Cyclophosphamide + Fludarabine phosphate + Nivolumab
Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK
Cytarabine + Fludarabine
Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine phosphate + LY3039478
Cyclophosphamide + Fludarabine + Rituximab
Cyclophosphamide + Fludarabine phosphate + Nivolumab
Fludarabine + Ibrutinib
Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus
Cyclophosphamide + Fludarabine phosphate + Tisagenlecleucel
Fludarabine + Olaparib
Cyclophosphamide + Fludarabine + IL-12 + LN-145 + Mesna
Cyclophosphamide + Fludarabine
Cytarabine + Fludarabine + Idarubicin + Uproleselan
Busulfan + Clofarabine + Fludarabine
CPX-351 + Cytarabine + Filgrastim + Fludarabine
Busulfan + Fludarabine + Venetoclax Flurdara (fludarabine phosphate) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)
Bendamustine + Fludarabine phosphate + Inotuzumab ozogamicin Besponsa (inotuzumab ozogamicin) consists of calecheamicin covalently linked to anti-CD22 antibody, which delivers calecheamicin into CD22-positive cells, leading to DNA damage and apoptosis (PMID: 24389139). Besponsa (inotuzumab ozogamicin) is FDA approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (FDA.gov).
Cyclophosphamide + Fludarabine + Mycophenolate mofetil
Bortezomib + Fludarabine + Melphalan
Iomab-B + Fludarabine
Dasatinib + Rituximab + Fludarabine
Aldesleukin + Cyclophosphamide + Fludarabine
anti-thymocyte globulin + Fludarabine + Melphalan
Fludarabine + Thiotepa + Cyclophosphamide
Cyclophosphamide + Fludarabine + Obinutuzumab
Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine phosphate Anti-BCMA CAR T Cells are T-cells that express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA), which may induce an enhanced anti-tumor immune response against BCMA-expressing tumor cells (PMID: 23344265).
Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax
Cytarabine + Dasatinib + Fludarabine + Idarubicin
Doxorubicin + Etoposide + Fludarabine + Vincristine
Bendamustine + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK
Rituximab + Fludarabine + EPOCH
Bendamustine + Fludarabine phosphate + Inotuzumab ozogamicin + Tacrolimus
Busulfan + Fludarabine + anti-thymocyte globulin
Cytarabine + Filgrastim + Fludarabine
Cyclophosphamide + Fludarabine + Ofatumumab
Busulfan + Fludarabine phosphate + Cyclophosphamide
Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine
KTE-C19 + Fludarabine phosphate + Cyclophosphamide
Busulfan + Sorafenib + Fludarabine
Aldesleukin + Cyclophosphamide + Fludarabine phosphate + IMA101 T cells
Fludarabine + Melphalan
Crenolanib + Cytarabine + Filgrastim + Fludarabine + Idarubicin +Mitoxantrone
Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus
Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab
Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab
Aldesleukin + anti-KRAS G12D mTCR cells + Cyclophosphamide + Fludarabine Anti-KRAS G12D murine T-cell receptor (mTCR) cells are peripheral blood lymphocytes that have been transduced with a murine T-cell receptor that recognizes KRAS G12D, which may result in decreased growth of tumors harboring KRAS G12D (PMID: 26701267).
Cytarabine + Fludarabine + Leucovorin + Panobinostat
Selinexor + Fludarabine phosphate + Cytarabine + Methotrexate + Prednisone
Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin
BC8-B10 + Cyclophosphamide + Fludarabine BC8-B10 is a radioimmunoconjugate that contains anti-CD45 monoclonal antibody BC8 with its lysine side groups conjugated with decoborate and labeled with Astatine (NCI Drug Dictionary). BC8-B10 prolongs survival of mice with disseminated murine leukemia in conjugation with bone marrow transplant (PMID: 23471305).
Cytarabine + Fludarabine + Prexasertib
Fludarabine + Ibrutinib + Pembrolizumab
Fludarabine + EPOCH
Cyclophosphamide + Fludarabine + Melphalan + Sirolimus